Laura Wilson didn't know about placenta donation until she was on the operating table.
"I had a cesarean, so they came in while I was being prepped for surgery," Wilson says in a YouTube video. "It was something I hadn't heard of before."
But when she was told placental tissue could be used to help people suffering from serious wounds, the mother of three boys quickly signed off on the consent forms.
"It was fun to think, ok, this could go to some good use instead of just going with everything else" in the medical waste bag, she says.
Wilson isn't the only mother to suddenly face a decision about placenta donation in the operating room. In an article on the motherhood website Scary Mommy, Caila Smith said she was in the hospital about to have an emergency C-section when a nurse asked her if she wanted to donate her twins' placentas. Another woman described getting a call from her doctor's office after scheduling her C-section and being asked to donate.
While most pregnant women have heard about cord blood donation, far fewer are familiar with placenta donation which can actually refer to the placenta, umbilical cord, and amniotic fluid, or "birth tissue." All are now sought as rich sources of stem cells. The eleventh-hour decision raises questions about just how informed patients' consent actually is, and what their donations are ultimately used for, particularly given the explosion in stem cell clinics offering questionable therapies.
"If women are being approached when they're in labor, about to go into a C-section, it's not the optimal time to be making decisions like that," Leigh Turner, PhD, a bioethicist at the University of Minnesota who has tracked the rise in stem cell clinics, told MedPage Today.
"Maybe they think it's for altruistic purposes," he added. "They may not realize there's a large for-profit marketplace out there."
It's difficult to track what donations are actually used for, although placental material does have seemingly legitimate applications in wound care and research. Still, those markets can be lucrative information that isn't usually offered to a mother, who is not compensated for the organ, when she is making her decision.
As more hospitals launch placenta donation programs, more mothers may be faced with the choice at an emotional, vulnerable time in their lives.
"I wanted to do this in case one day my boys would need this," Wilson says in the video, which was posted to YouTube by a company called Birth Tissue Recovery to promote its placenta donation program.
Rise in Placenta Donations
St. David's Medical Center in Austin, Texas, launched its placenta donation program about a year and a half ago in partnership with GenCure, a company that describes itself as non-profit and says it "applies advances in regenerative medicine to help heal patients suffering from trauma, disease or the aging process" on its website.
GenCure's placenta donation program involves collecting the placenta and the umbilical cord, according to spokesperson Ashley Frolick. The company also collects cord blood through the Texas Cord Blood Bank, which it owns.
In most cases, mothers are told about the option to donate when they arrive at the hospital, Frolick said, although they are only eligible if they are having a C-section, which is often an emergency situation.
Michelle Kocks, RN, coordinator of the placenta donation program at St. David's, said patients are persuaded by the fact that they're helping others, and because the placenta will otherwise be discarded as medical waste -- a potential incentive for hospitals to run programs, as they would otherwise have to pay for medical waste disposal. (Hospitals are uniformly mum about why, exactly, they agree to facilitate donations that go to outside entities, or whether money changes hands.)
"Once [women] learn about the benefits ... they love being able to be a part of the program," Kocks told MedPage Today, adding that about 20% of eligible women who undergo C-section deliveries become donors. Frolick said nurses and doctors are not paid for referrals, and neither are the women who are giving birth.
Other hospitals are launching placenta donation programs. Rochester General Hospital added theirs in July, and Mount Carmel St. Ann's Hospital in Westerville, Ohio, had its first donation in April. Both are working with MTF Biologics, which also claims non-profit status and says it focuses on bone and skin grafts.
St. Joseph Mercy in Ann Arbor, Michigan, launched its program this summer in partnership with Gift of Life Michigan, the first hospital in the state to do so.
Other hospitals with new programs include Sisters of Charity Hospital in Buffalo, New York, which works with ConnectLife (formerly UNYTS); and Maple Grove Hospital in Minnesota, which works with for-profit MiMedx.
MiMedx has been plagued by scandals including charges involving its marketing and accounting practices, and allegations that it shipped more product than had been ordered and booked that as sales. This summer, the Department of Veterans Affairs advised its facilities not to use injectable amniotic tissue products from the company for not meeting purity and sterility standards. The VA also warned against using such products for managing plantar fasciitis, tendonitis, or osteoarthritis "since evidence is currently limited or lacking" for their efficacy.
MiMedx runs placentadonation.com through its subsidiary MiMedx Tissue Services.
Loralei Thornburg, MD, an ob/gyn at the University of Rochester Medical Center, said her institution discussed a placenta donation program with ConnectLife, but didn't create one because they treat too many high-risk cases.
"Most of the hospitals where you see it being done tend to [have] lower-risk, more normal populations," Thornburg said. "One of our lower-risk hospitals started looking into it ... because that's who's eligible. I do primarily high risk. They don't want a 28-week placenta with preeclampsia."
GenCure partners with six hospitals in Texas on placenta donation. Frolick said the birth tissue that it collects is provided to "partners who will then create therapeutic products that may be used to help treat burns, diabetic ulcers, traumatic injuries, and can go on to develop other FDA-approved therapies."
That could include stem cell therapies, Frolick said. These treatments have long taken advantage of a grey area in FDA regulation, which stipulates that human cell and tissue products are exempt from the extensive and expensive drug or biologic approval process as long as they meet certain criteria.
'It's Going to Be Marked Up and Sold Again'
Summa Health, a health system in northern Ohio, offers "placenta tissue injections" for "damaged tissue found in tendons, ligaments, inflamed tissue and degenerated joints."
A PubMed search reveals no studies of the therapy for any indication.
"I'm not aware of anything in this whole sector being shown to be effective or safe with good, solid data," stem cell researcher Paul Knoepfler, PhD, of the University of California Davis, told MedPage Today.
The rise in placenta and birth tissue donation parallels an increase in unregulated stem cell clinics around the country, with well over 1,000 today, up from 570 when Turner first started tracking them in 2016. The FDA has long waged war with these clinics, which purport to treat everything from pain to Parkinson's disease with stem cells. A federal judge handed the agency a victory in June when it ruled that FDA could block Florida-based U.S. Stem Cell from injecting patients with a stem-cell "extract" made from their own fat cells.
Given the ruling, Turner said clinics may shift from using fat or bone marrow to procure stem cells, to placental or birth tissue products -- also referred to as amniotic stem cell treatments -- especially since they can just be bought and injected. Also, they don't require collecting or processing material from patients.
But the amniotic stem cell supply chain isn't easy to trace.
"It's the part of the marketplace that's most obscured, and that we know the least about," Turner said.
Summa Health did not return a request for comment as to where it gets the material for its placenta tissue injections.
An investigation by ProPublica found that one company, R3 Stem Cell, sourced its amniotic stem cell products from Utah Cord Bank, which began as a private bank where parents stored cord blood and other birth tissue.
Apart from stem cell therapies, other uses of placental material such as wound care can also be lucrative, especially since these products also fall under FDA's "minimally manipulated" and "homologous use" requirements for human cell and tissue products, side-stepping the agency's costly and time-consuming approval process.
John Lantis, MD, a wound care expert at Mount Sinai Hospital in New York, said he's skeptical of claims that amniotic and placental skin grafts provide superior healing compared with regular skin grafts.
"The number of products out there delivering real stem cells is highly questionable," Lantis told MedPage Today. "No one knows if active placental tissues are better. No one has studied it in a meaningful fashion, so a regular skin graft may work just as well."
One of the most widely used products for lower extremity wounds, Lantis said, is EpiFix, which is made by MiMedx. It is synthesized from "dehydrated human amnion/chorion membrane" -- placental material -- according to the company's website. In 2013, the FDA warned the company about marketing the product without approval, which the firm eventually obtained.
If women knew more about the money, power, and scandal behind their donations, they might see donation differently, Turner said.
"What if women were given the full account, that some biobank is going to acquire it, process it, assign it value, and then it's going to be marked up and sold again," Turner said. "Some women might think twice."
2020-03-01T00:00:00-0500
last updated 01.03.2020
See the article here:
The Afterlife of Afterbirth - MedPage Today
- Cord Blood Banking - Stanford Medicine Children's Health - May 8th, 2024
- Umbilical Cord Blood Transplants: Current Status and Evolving Therapies - May 8th, 2024
- Embattled Cordlife receives letter of demand from client for breach of contract - The Straits Times - May 4th, 2024
- From Cord Blood to Microbiome; The evolution of Rotary's gift to the people of WA - Lifeblood - May 2nd, 2024
- Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune ... - Nature.com - April 28th, 2024
- Hitting the pavement for cord blood research | Cranbourne Star News - Cranbourne Star News - April 28th, 2024
- One year to test 200 Cordlife samples 'totally unjustified': Global cord blood banking experts - The Straits Times - April 15th, 2024
- Clinical trial: First cardiac bioimplants for treatment of myocardial infarction using umbilical cord stem cells - Medical Xpress - April 7th, 2024
- The umbilical cord: a rich and ethical stem cell source to advance ... - March 30th, 2024
- Story of discovery: getting a Notch up on cord blood cell ... - March 30th, 2024
- Cord Blood Transplants | Memorial Sloan Kettering Cancer Center - March 30th, 2024
- Therapeutic effect and study of human umbilical cord blood mononuclear cells in patients with ischaemic bowel ... - Nature.com - March 17th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024: The Vast Majority of the Global Cord Blood Market is Now ... - PR Newswire - March 15th, 2024
- Improving Transplant Outcomes and Cell Therapy Approaches - RegMedNet - March 9th, 2024
- The inhibition of ADAM17 in cord blood stem cell-derived CD16+ NK cells to enhance their cytotoxicity against acute ... - ScienceDirect.com - March 1st, 2024
- Beating Blood Cancer through Recycling - a Community crowdfunding project in Liverpool by Kate Williams - Crowdfunder UK - February 24th, 2024
- Cord Blood Registry (CBR ) by CooperSurgical and Fulgent Genetics Launch Innovative Genetic Testing - Investing.com Canada - February 9th, 2024
- Young cancer patient with 'no hope' of recovery saved by baby's umbilical cord - Study Finds - February 9th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN - January 26th, 2024
- Finding the optimal combination of anticancer drug administration for the conditioning of cord blood transplantation - Medical Xpress - January 26th, 2024
- Cord Blood Banking Market Sales and Revenue Report 2023-2032 - WhaTech Technology and Markets News - January 26th, 2024
- Global Cord Blood & Tissue Banking Industry Report 2024 - The Vast Majority of the Global Cord Blood Market is Now ... - ACROFAN USA - January 24th, 2024
- Global Biobanking Market Size To Exceed USD 97.5 Billion By 2032 | CAGR of 5.8% - GlobeNewswire - January 24th, 2024
- The use of cryopreservation in life saving research - The Manufacturer - January 24th, 2024
- CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies - Medical Xpress - January 18th, 2024
- Cord blood banking comes at a high cost to babies - STAT - STAT - January 18th, 2024
- Global Cord Blood and Tissue Banking Industry Gains Traction Amidst Surging M&A Activity and Technological Advances - PR Newswire - January 16th, 2024
- Donating Bone Marrow and Stem Cells: The Process and What To Expect - On Cancer - Memorial Sloan Kettering - January 11th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 4th, 2024
- askST: Can cord blood units be transferred from one bank to another? - The Straits Times - December 27th, 2023
- Timeline: Cordlife's mishandling of cord blood units in Singapore - CNA - December 15th, 2023
- Next-Level Evolution: Enhancing the Human Body With Anthrobots ... - Securities.io - December 5th, 2023
- Fred Hutch at ASH: Gene therapies for sickle cell, how to improve ... - Fred Hutchinson Cancer Center - December 5th, 2023
- Enhancing the immunosuppressive properties of human umbilical ... - Phys.org - December 1st, 2023
- Global Status and Trends for Thromboangiitis Obliterans | JPR - Dove Medical Press - December 1st, 2023
- Early Stage Cell Therapy Trial Shows Promise in Treating Progressive Multiple Sclerosis - University of Colorado Anschutz Medical Campus - December 1st, 2023
- Global Medical Specialty Bag Market is Expected to Reach US$ 9.4 Billion by 2034, Rising at a Steady 4.7% CAGR | Future Market Insights, Inc. - Yahoo... - November 29th, 2023
- Repeated concussions can alter heart activity and impact the heart ... - Philippine Canadian Inquirer - November 29th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - PharmiWeb.com - November 27th, 2023
- Vita 34 increases revenue and earnings in Q3 2023 and further ... - Marketscreener.com - November 25th, 2023
- FY 2021 VA-Funded Projects - VA's Office of Research and Development - November 25th, 2023
- New study aims to expand access to stem cell transplant using ... - Healio - November 23rd, 2023
- Impact of GVHD Prophylaxis on CMV Reactivation and Disease ... - Cancer Network - November 23rd, 2023
- The Top 25 Women Leaders in Biotechnology of 2023 - The Healthcare Technology Report. - November 21st, 2023
- First Edition: November 20, 2023 - KFF Health News - November 21st, 2023
- An essential guide to the building blocks of life - Gates Notes - November 21st, 2023
- A Simple Way to Save Premature Babies - The New York Times - November 19th, 2023
- Perspectives of current understanding and therapeutics of Diamond ... - Nature.com - November 17th, 2023
- Brain Organoids: Should They Be Considered People? - BBVA OpenMind - November 17th, 2023
- Understanding the cause of childhood Alzheimer's - ASBMB Today - November 17th, 2023
- Peripheral nerve regeneration through nanofiber scaffolds | IJN - Dove Medical Press - November 15th, 2023
- Are STEM CELL EXOSOMES the secret to a 'snatched' jawline? Discover the products that influencers are claiming - Daily Mail - November 13th, 2023
- CAR-NK: The next generation in hematological malignancy treatment - News-Medical.Net - November 13th, 2023
- Regenerative Medicine | Top Regenerative Medicine Solution ... - Healthcare Tech Outlook - November 13th, 2023
- Stem cell therapy, emerging solution to slow down ageing - Punch Newspapers - November 13th, 2023
- Improving Cord Blood Transplantation Outcomes for Adults With ... - On Cancer - Memorial Sloan Kettering - November 11th, 2023
- 8 Ways To Save Lives With Canadian Blood Services & You Can ... - Narcity Canada - November 11th, 2023
- Internal investigation by Vita 34 AG reveals irregularities related to a ... - Marketscreener.com - November 11th, 2023
- 'We worried the worst would happen' - Yorkshire Children's Trust ... - The Yorkshire Post - November 11th, 2023
- Minor GPI(-) granulocyte populations in aplastic anemia and healthy ... - Nature.com - November 9th, 2023
- Repeated treatment with ProTrans is immunologically safe ... - Marketscreener.com - November 7th, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells - Benzinga - November 7th, 2023
- Health Canada issues warning on cord blood stored in Edmonton - CBC News - November 3rd, 2023
- Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting - Yahoo... - November 3rd, 2023
- Dynamic Stem Cell Therapy Uncovers Research in Advance ... - InvestorsObserver - November 3rd, 2023
- Go with the flow and achieve hearing restoration - Drug Discovery News - November 3rd, 2023
- Cell Therapy Market to Witness Exponential Growth by 2031 ... - Argyle Report - November 1st, 2023
- Cross-talk between Myeloid and B Cells Shapes the Distinct ... - Cancer Discovery - November 1st, 2023
- Comparison of effects of HucMSCs, exosomes, and conditioned ... - Nature.com - October 28th, 2023
- The structural and functional complexity of the integrative ... - Science - October 28th, 2023
- Global Primary Cells Market to Witness Growth at 11.41% CAGR to ... - GlobeNewswire - October 26th, 2023
- Hma-Qubec celebrates 25 years of giving life in anniversary ad - - The Message - October 26th, 2023
- Improvement of thermal-stability of chondroitinase ABCI immobilized ... - Nature.com - October 26th, 2023
- Sydney Couple Overcomes Sperm Antibody Issue to Welcome Baby - OPP.Today - October 24th, 2023
- New Research Reveals Surprising Issue with Sperm and Fertility - CityLife - October 24th, 2023
- Biobanking Market to Observe Prominent CAGR of 6.10% by 2029 ... - PharmiWeb.com - October 21st, 2023
- TV shows like BBC's Call The Midwife and C4's One Born Every Minute 'are inaccurately depicting childbirth' an - Daily Mail - October 19th, 2023
- Advances in medical and technological research and SCI - Clyde & Co - October 18th, 2023
- Prognostic Value of Hematogones in Patients With Hematopoietic ... - Cureus - October 18th, 2023
- Stem-Cell Therapy: Filling Gaps in Oro-Maxillofacial Region - Cureus - October 18th, 2023
Recent Comments